The company is a large pharmaceutical industry group listed in Shanghai and Hong Kong. The company's main business covers the pharmaceutical industry, distribution and retail, with an operating income of 186.6 billion yuan in 2019, ranking among the highest in the country. It was selected for the Shanghai Composite 180 Index, the Shanghai and Shenzhen 300 Index sample stocks, and the Morgan Stanley China Index (MSCI). Shanghai Pharmaceutical promotes the core corporate values of “innovation, integrity, cooperation, inclusiveness and responsibility”, is committed to persevering, improving people's quality of healthy life, and striving to become a leading brand drug manufacturer and health service provider that is respected and has an industry reputation. The company's main business covers the pharmaceutical industry and pharmaceutical business. Corporate honors: Ranked 473rd in the “Fortune” World 500 in 2020, and was one of only two Chinese pharmaceutical companies; ranked 57th in the 2020 Fortune China 500 published by “Fortune Fortune” (Chinese version); ranked 1009th in the 2020 Fortune 2000 Global Enterprises published by “Forbes”, ranked 2nd in the overall strength of China Pharmaceutical Group; ranked 2nd in the “China Pharmaceutical Distribution Industry Development Report” published by the Ministry of Commerce, etc.
No Data